Metformin is recommended as first-line therapy for type 2 diabetes (T2D) (1) , and currently is used by over 120 million patients worldwide. It ameliorates hyperglycemia by inhibiting hepatic gluconeogenesis, and increasing peripheral glucose uptake (2) . It may also increase gut glucose utilisation (3) . At a molecular level it has been suggested that metformin interferes with glucagon signalling (4) , and more recently, that it inhibits mitochondrial glycerol-3-phosphate dehydrogenase, leading to reduction of hepatic gluconeogenesis (5) .
Activation of AMP-activated protein kinase may mediate metformin effects on lipid metabolism and insulin sensitivity (6) . Metformin is recommended as first-line therapy for T2D because of its efficacy, safety (lack of weight gain, low risk of hypoglycemia), relatively low cost, and potential cardiovascular benefit (7).
Metformin treatment is, however, frequently associated with gastrointestinal (GI) side-effects (20-30% of patients) (2) and this can negatively affect quality of life and adherence in T2D patients (8) . Approximately 5% of patients develop severe GI symptoms and discontinue the treatment with metformin, which could deprive them of the beneficial effects of the drug.
Common metformin GI symptoms include nausea, diarrhea, vomiting, bloating and abdominal pain (9) . The pathophysiology of metformin induced GI intolerance is unclear, although different hypotheses have been proposed, including stimulation of intestinal serotonin secretion, changes in incretin and glucose metabolism, and bile-salt malabsorption (9) . It is hypothesised that GI intolerance is related to high concentration of metformin in the intestine after oral administration of the drug (10, 11) .
Metformin is an organic cation, and carrier proteins mediate its oral absorption, hepatic uptake and renal elimination. Several solute carrier (SLC) transporters, expressed in the membranes of the enterocytes, could be involved in the absorption of metformin from the intestinal lumen, including organic cation transporter 1 (OCT1), plasma membrane monoamine transporter (PMAT), carnitine/cation transporter 1 (OCTN1) and organic cation transporter 3 (OCT3) (12) (13) (14) (15) . While there are no established common loss-of-functions variants of other metformin gut transporters, the human OCT1 gene (SLC22A1) is highly polymorphic, and four OCT1 variants: R61C (rs12208357), M420del (rs72552763), G401S (rs34130495) and G465R (rs34059508), showed reduced metformin transport in vitro (16) . In addition to genetic variation, a number of commonly prescribed drugs have been shown to inhibit transport via OCT1 in vitro (e.g. tricyclic antidepressants (TCAs), proton pump inhibitors (PPIs), alpha-adrenoreceptor antagonists, calcium-channel blockers (verapamil and diltiazem)) (17) .
We hypothesised that reduced transport of metformin by OCT1 could increase metformin concentration in the intestine, resulting in increased risk of GI intolerance and drug discontinuation. Therefore we assessed the role of five reduced-function variants in OCT1 (R61C, C88R (rs55918055), G401S, M420del, and G465R), and concomitant use of OCT1 inhibiting drugs in metformin intolerance, in a large cohort of metformin treated T2D patients from Tayside, Scotland.
RESEARCH DESIGN AND METHODS
Study Population. In this observational cohort study, we identified patients with T2D who were receiving treatment with metformin, using data from the Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) database. The GoDARTS resource includes nearly 10,000 patients with T2D. Since October 1997, DNA was collected from the patients for genetic studies. Retrospective and prospective longitudinal data is collected on each individual with T2D from diagnosis of diabetes, including prescribing, biochemistry and clinical data, which can be obtained in an anonymised form. The GoDARTS study was approved by the Tayside Medical Ethics Committee. Informed consent was obtained for all participants. The use of the GoDARTS bioresource for the study of metformin pharmacogenetics was approved by the Tayside Tissue Bank.
The study included all GoDARTS patients with T2D, who were incident users of metformin in the period from 1 st January 1994 to 1 st June 2011.
Definition of Intolerance.
We established a proxy phenotype of metformin intolerance based upon prescribing patterns. Patients who stopped metformin within the first 6 months of treatment (immediate release form, IR), and switched to another oral hypoglycemic agent, including metformin slow release forms, within 6 months of the last metformin IR prescription, were identified as intolerant. We excluded patients who switched to insulin within 6 months of the last metformin prescription, as well as patients who ever received daily dose of metformin immediate or slow release formulations, of 2000 mg or more.
Patients who were prescribed ≥ 2000 mg of metformin IR form for more than 6 months were defined as tolerant. Patients in both groups with serum creatinine levels above 120µmol/L were excluded from the analysis.
From a total of 6,265 patients, incident users of metformin with T2D, based on our definition, we classified 251 patients as intolerant, and 1,915 patients as tolerant (2,166 patients totally).
Anthropometric and Biochemical Variables. Values closest to metformin index date were taken for weight, BMI, and serum creatinine levels (within one year either side of metformin start), and for HbA 1c (within 6 months prior to metformin start). Creatinine clearance was estimated using the Cockcroft-Gault formula (18) .
Metformin Dose. Daily dose of metformin was defined as the last prescribed dose for intolerant patients, and as an average dose in the first 6 months of metformin treatment for tolerant patients.
OCT1 Inhibiting Medications.
We identified all patients who were prescribed, concomitantly with metformin, medications shown to inhibit OCT1 activity in vitro. This included prescriptions for tricyclic antidepressants (TCAs) (19, 20) , citalopram (17, 19) , proton pump inhibitors (PPIs) (21) , verapamil (19, 20) , diltiazem (19) , doxazosin (19, 20) , spironolactone (19, 20) , clopidogrel (22) , rosiglitazone (23), quinine (17, 19) , tramadol (19, 24) , and codeine (25) . There were only few or no prescriptions for other OCT1 inhibiting drugs (including prazosin, disopyramide, quinidine, repaglinide, propafenone, ketoconazole, morphine, tropisetron, ondansetron, antipsychotics, tyrosine kinase inhibitors) (17, 19, 20, 23, (25) (26) (27) .
Genotyping. M420del and R61C variants were genotyped previously in the whole of GoDARTS using TaqMan genotyping assays (Applied Biosystems) (28) . Genotypes of the other three variants were imputed from existing genome-wide data on 7319 GoDARTS patients using the 1000 genome reference panel and software IMPUTE2 (29, 30 
RESULTS

Metformin intolerance phenotype
The characteristics of metformin intolerant and tolerant patients are shown in Table 1 .
Intolerant patients were on average 10 years older (p < 0.001), were more commonly women (p < 0.001), had lower weight and BMI (p < 0.001), lower creatinine clearance (p < 0.001),
lower HbA 1c (p =0.003), and were treated with lower metformin dose (p < 0.001).
To assess whether we had identified a group who developed gastrointestinal (GI) side-effects after starting metformin, we explored the use of GI drugs that could be prescribed for GI sideeffects (compound alginates, antispasmodics, antidiarrhoeals and antiemetics), between the two groups before and after metformin commencement (Supplementary Table 1 ). Consistent with a prescribing pattern suggesting GI intolerance, more patients were treated with antidiarrhoeal medications after metformin initiation in the intolerant group than the tolerant group. Although not statistically significant, there was also a similar trend for higher use of antispasmodics and other drugs altering gut motility, as well as antiemetics, after metformin initiation in the intolerant compared to the tolerant group (Supplementary Table 1 ). Therefore we studied the use of histamine H 2 -receptor antagonists (H2RAs) between intolerant and tolerant patients, as these are used for the same indication as PPIs yet do not inhibit OCT1 (19) . There were no significant differences in percentage of patients treated with H2RAs (19 (7.6%) intolerant vs. 117 (6.1%) tolerant patients, p = 0.370) in the intolerant group and the tolerant group, suggesting that the result seen for PPIs does reflect OCT1 inhibition.
OCT1 interacting drugs and metformin intolerance
OCT1 genotypes and metformin intolerance
We explored the linkage disequilibrium between the five OCT1 variants by haplotype analysis using directly genotyped exomechip data. As shown in Supplementary table 3, C88R and G465R substitutions only occurred with M420del variant, while R61C and G401S (16, 27, 33) . Further diplotype data in Supplementary Table 4 showed that the number of reduced-function haplotypes in each patient could be simply characterized by the total number of variant alleles in R61C, M420del and G401S (OCT1 combined genotype).
The numbers of patients in the intolerant and tolerant group according to the number of deficient OCT1 alleles are shown in the Supplementary Table 5 . There was a significant difference in the combined genotype frequency between the two groups in the recessive model (p < 0.001).
The combined genotype was added to the logistic regression model, adjusted for age, sex, weight, and the overall use of OCT1 inhibiting drugs (Table 2 ). In addition to the concomitant treatment with OCT1 inhibiting medications, the presence of two reduced-function alleles was independently associated with intolerance to metformin (OR=2.41, 95% CI 1.48-3.93, p < 0.001). When patients were grouped according to combination of OCT1 genotype and the use of OCT1 inhibiting drugs, carriers of two low-activity alleles who were also treated with OCT1 interacting drugs, had four-fold higher odds of intolerance compared to patients with one or no deficient alleles who were not taking OCT1 inhibitors (OR=4.13, 95% CI 2.09-8.16, p < 0.001) ( Table 3 ).
Sensitivity analysis
Since there were large differences in age and sex between cases and controls, we carried out a sensitivity analysis by comparing the intolerant group (n=231) with age-and sex-matched subgroup of tolerant patients (n=709). In this sensitivity analysis we confirmed the main To guard against potential bias originating from the imputed data, we performed another sensitivity analysis in a subset of 660 patients using only directly genotyped data by TaqMan and exomechip. Carriage of two dysfunctional OCT1 alleles showed significant association with intolerance even in this much smaller cohort (OR=2.99, 95% CI 1.40-6.38, p=0.005, Supplementary Table 8 ).
To test our definition of intolerance, we carried out additional analyses excluding intolerant patients who had more than 2 metformin prescriptions, and excluding patients who transitioned to metformin slow release forms. Exclusion of these two small subgroups did not alter the results (data not shown).
DISCUSSION
A number of studies have investigated effects of genetic variants on metformin efficacy (34), including the first genome-wide association study of metformin response performed by our group (35) . However, so far, only one small study has examined the pharmacogenetics of metformin GI side-effects in T2D (36) and no studies have investigated the use of coprescribing on risk of metformin intolerance. To our knowledge, this is the first study that addressed the genetics of metformin intolerance, and the role of OCT1, in a large cohort of T2D patients. We found that concomitant use of drugs that inhibit OCT1 increases metformin intolerance, with some drugs such as verapamil increasing odds of intolerance seven fold. In addition, we showed a significant effect of OCT1 genotype on intolerance: patients carrying two OCT1 reduced-function alleles had more than twice the odds of intolerance compared to Although our results provide strong evidence that inhibition of OCT1 transport increases the risk of GI intolerance, the precise mechanism for this remains uncertain. Results from earlier studies suggested basolateral localization of OCT1 in enterocytes (14, 37, 38) , however a recent study demonstrated apical localization of OCT1 in Caco-2 cell monolayers and mouse and human enterocytes (15) . If OCT1 has a role in efflux of metformin (either via the basolateral or apical route), then inhibition could increase metformin concentration in the enterocytes. Alternatively, if OCT1 has a role in transport of metformin from the lumen into the enterocytes, then OCT1 inhibition could increase luminal metformin concentration.
Although proposed hypotheses of metformin GI intolerance are inconclusive, and it is unclear whether adverse effects could be attributed to the drug present in the mucosa or in the lumen, increased metformin concentrations in the gut may affect intestinal serotonin concentration (39), bile salt absorption (40) or potentially alter the microbiome (41).
An alternative mechanism for the increased metformin intolerance with reduced OCT1 transport is that OCT1 inhibition is altering systemic concentrations of metformin, and it is the higher circulating metformin concentrations that result in metformin intolerance.
However, the role of OCT1 in metformin pharmacokinetics has been extensively studied and the data are unclear. There were no differences in the pharmacokinetic properties of metformin between Oct1 (-/-) and Oct1 (+/+) mice after oral application (42) . On the other hand, results of the studies on OCT1 reduced-function variants and metformin pharmacokinetics in humans have been contradictory (32, 33, 42) . In a study by Christensen et al, the number of reduced-function alleles was associated with lower trough metformin Page 12 of 36 Diabetes levels (33) . It has been suggested that decrease in metformin levels could be a combined result of reduced intestinal absorption, an increased renal clearance (32) , and decreased distribution (33) . In contrast, in a study in 20 healthy volunteers, patients carrying one or more OCT1 reduced-function alleles had slightly higher metformin plasma concentrations than patients with wild-type OCT1 (42) . However, in this study, only two patients had two inactive alleles, and it has been suggested that major changes may be seen only in subjects carrying two OCT1 low-activity alleles (recessive model) (33, 43) . This is in line with our results, as a significant effect of OCT1 genotype on metformin intolerance was only observed in the recessive model. Additional studies are needed to clarify contradictory findings on the effect of OCT1 variants on metformin pharmacokinetics, as well as response (16, 28, 33) .
We show that use of concomitant drugs that inhibit OCT1 transport in vitro increases risk of metformin intolerance. Many drugs used clinically have been identified as OCT1 inhibitors in vitro (17) . We included ten drugs and two drug classes in our analysis, based on their frequency of use in the study cohort and their reported half maximal inhibitory concentrations (IC 50 ). Strong inhibitory effects on OCT1-mediated metformin transport in vitro were demonstrated for verapamil (20) , rosiglitazone (23) , PPIs (21) and clopidogrel (22) . For other included drugs/drugs classes in our study, in vitro inhibition measurements with metformin as OCT1 substrate were not performed. However, based on the IC 50 values for 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) transport, spironolactone, most of the TCAs, diltiazem, doxazosin and citalopram were classified as strong OCT1 inhibitors (19, 20) , while quinine and tramadol were weaker inhibitors (17, 19, 24) . A recent study showed that codeine could also significantly inhibit OCT1-mediated uptake (25) . Metformin transport however may be more sensitive to inhibition compared to the model substrates because of its lower apparent affinity (20) .
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We see striking differences between drug classes, with large effects particularly seen for verapamil, PPIs, doxazosin, codeine and citalopram. We report the largest effect of co- We observed higher use of antiemetic drugs (drugs used in nausea and vertigo) in intolerant group prior to and after metformin initiation. It is unclear the reason for this and it may reflect Page 14 of 36 Diabetes the small numbers in these groups. However, adjustment for prior use of antiemetics, as well as exclusion of these patients, did not affect significantly our results. From 14 intolerant patients with prior use of these drugs, 8 were treated with prochlorperazine and 4 with domperidone. It is interesting, however, that prochlorperazine showed also weak inhibition of ASP transport by OCT1 (19) , and domperidone has recently been identified as OCT2 inhibitor (46) .
Other identified significant risk factors for metformin intolerance in our study were older age and female sex, with a trend towards lower weight. Estimated creatinine clearance was calculated based on an equation with these three variables, and thus was significantly different between the two groups, although creatinine levels were similar. Our results are in agreement with the findings of a small study that investigated genetics of common metformin GI sideeffects (36) . The presence of side-effects in this prospective study correlated positively with age, and 76% of 53 cases were women. Interestingly, the authors analysed 7 variants in OCT1, OCT2 and MATE1 genes, reporting that, of these, two common OCT1 polymorphisms in high linkage disequilibrium with each other were associated with increased prevalence of metformin side-effects (M408V and 8 bp insertion), while R61C, M420del, and G465R variants, or OCT1 haplotypes, showed no association (36) . However, M408V showed normal uptake of metformin in vitro (16) , and the function of 8 bp insertion is unknown. In contrast to our study, the phenotype used was that of mild intolerance, and no interacting drugs were studied. The small sample size of the previous study means the power to identify effects of the OCT1 reduced-function variants was limited.
The main limitation of our study is the surrogate phenotype of metformin GI intolerance based on discontinuation of the drug in the first months of treatment. However, patients were (2) . This number is in line with our findings, as we identified 251 from a total of 6,265 incident metformin users as intolerant (4%). We also show that the intolerant group have increased use of anti-diarrheal drugs, and tendency of higher use of other GI drugs, after metformin initiation, supporting that they are having GI problems. Using a similar approach, we successfully developed proxy phenotype for statin intolerance previously (47) .
Our study has potential clinical impact. Our data suggest that concomitant therapy with OCT1 inhibiting drugs, like PPIs and verapamil, is a risk factor for developing intolerance, and this could be avoided by prescribing alternative medications, that do not interact with OCT1, to patients suffering from side-effects. This is particularly true for the 8% of the population with two inactive OCT1 alleles, who are over four fold more likely to develop intolerance with coprescribed OCT1 inhibiting drugs. Avoiding OCT1 inhibiting drugs in these individuals would prevent reduced efficacy associated with suboptimal metformin dosage, and potential cessation of metformin treatment and its substitution with second-line therapies. This needs to be established in a clinical trial before such recommendation can be implemented into practice.
In conclusion, we have identified age, female sex, reduced-function alleles of OCT1 and the concomitant use of OCT1 inhibiting medications, as risk factors for metformin intolerance.
Future prospectively designed studies are needed to substantiate our findings and to identify other possible predictive biomarkers of metformin intolerance. Metformin daily dose (mg) 1000 (1000-1000) 1000 (1000-1500) <0.001
Data are presented as means±SD, medians (interquartile range), or numbers (percentages). TCAs, tricyclic antidepressants; PPIs, proton pump inhibitors; OR, odds ratio; LCL, lower confidence limit; UCL, higher confidence limit. PPIs, proton pump inhibitors; OR, odds ratio; LCL, lower confidence limit; UCL, higher confidence limit. Data are presented as numbers of patients (percentages). TCAs, tricyclic antidepressants; PPIs, proton pump inhibitors. *Codeine was used as an opioid analgesic (BNF code 4.7.2) and a cough suppressant (BNF code 3.9.1), and not as an antimotility drug (BNF code 1.4.2).
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